Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results

By Cory Renauer – Updated May 21, 2020 at 4:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A double-sided antibody with blockbuster potential shrank tumors for relapsed multiple myeloma patients who have run out of treatment options.

On Tuesday, Johnson & Johnson (JNJ -1.10%) released positive results from a human proof-of-concept trial with relapsed multiple myeloma patients and teclistamab, the bispecific antibody formerly known as JNJ-7957. At the American Society of Clinical Oncology's conference, which was held virtually, J&J presented interim results that strongly suggest teclistamab can make a significant difference for patients who have relapsed after receiving between two and 14 lines of treatment.

Bringing the fight to multiple myeloma 

Today's cancer therapies are limited to single targets, but this early clinical-stage candidate targets both B-cell maturation agents (BCMA) often found on cancerous cells and CD3 found on T-cells at the same time.

Healthcare provider and an elderly patient in pajamas.

Image source: Getty Images.

As of Jan. 31, 66 patients had been treated with a wide range of teclistamab dosages. While there wasn't much activity in the lower dose cohorts, eight out of 12 patients responded to the strongest dosage being evaluated. Among the responders in the high dose cohort, two tested negative for signs of minimal residual disease more than a year after the beginning of the trial.

Next steps

Each time a multiple myeloma patient relapses or fails to respond to a line of treatment, their chances of responding to the next one diminish significantly. Among 66 patients treated with ranging doses, 36% experienced side effects severe enough to warrant hospitalization. This isn't a terrific safety profile, but it will probably be more than acceptable if more patients treated with a high dosage of teclistamab show impressive responses.

Based on the strong early results for teclistamab, Johnson & Johnson will expand the study to include more patients treated with high dosages of the drug candidate. 

Cory Renauer owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$164.53 (-1.10%) $-1.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.